期刊文献+

Research and clinical value of antibacterial-application software 被引量:2

Research and clinical value of antibacterial-application software
原文传递
导出
摘要 The resistance to antibacterials therapy has been increasing in recent years,^1,2 The rational use ofanti-bacterials should include: (1) choosing the right drugs according to the scope of their antibacterials function and making sure they are suitable for treatment of the microorganisms that have induced the infection;^3 (2) administering anti-bacterials by a rational method according to their pharmacodynamics;^4 (3) paying attention to the systemic condition of the patients according to pharmacokinetics of the drugs.^5,6 The resistance to antibacterials therapy has been increasing in recent years,^1,2 The rational use ofanti-bacterials should include: (1) choosing the right drugs according to the scope of their antibacterials function and making sure they are suitable for treatment of the microorganisms that have induced the infection;^3 (2) administering anti-bacterials by a rational method according to their pharmacodynamics;^4 (3) paying attention to the systemic condition of the patients according to pharmacokinetics of the drugs.^5,6
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2008年第1期86-89,共4页 中华医学杂志(英文版)
关键词 antibacterial-application software ANTIBACTERIAL pharmacodynamic/pharmacokinetic parameters antibacterial-application software antibacterial pharmacodynamic/pharmacokinetic parameters
  • 相关文献

同被引文献20

  • 1庞京生.在教学互动中实现学以致用、教学相长——“全程互动式案例教学”模式的探索与实践[J].北京广播电视大学学报,2006(1):33-38. 被引量:20
  • 2梁永杰,翟晓波,何礼贤.抗菌药应用软件的研发及其临床意义[J].上海医药,2007,28(4):172-173. 被引量:1
  • 3Zeglin MA,Pacoss J,Bisognano JD.Hypertension in the very elderly:Brief review of management[J].Cardiol J,2009,16(4):379-385.
  • 4Naranjo CA,Busto U,Sellers EM,et al.A reliable method for estimating the probability of adverse drug reactions[J].Clin Phar Ther,1981,30(2):239-245.
  • 5Schumock GT,Thoroton JP.Focusing on preventability of adverse drug reactions[J].Hosp Pharm,1992,27(6):538.
  • 6Johnson JM,Tanner LA.Postmarketing surveillance:curriculum for the clinical pharmacologist,Part Ⅱ:Clinical and regulatory considerations[J].J Clin Pharmacol,1993,33(11):1015-1022.
  • 7Gurwitz JH,Field TS,Harrold LR,et al.Incidence and preventability of adverse drug events among older persons in the ambulatory setting[J].JAMA,2003,289(9):1107-1116.
  • 8Thomas EJ,Brennan TA.Incidence and types of preventable adverse drug events in elderly patients:population based review of medical records[J].BMJ,2000,320(7237):741-744.
  • 9Bates DW,Miller EB,Cullen DJ,et al.Patient risk factors for adverse drug events in hospitalized patients.ADE Prevention Study Group[J].Arch Intern Med,1999,159(21):2553-2560.
  • 10Gholame K,Shalviri G.Factors associated with preventability,predictability and severity of adverse drug reactions[J].Ann Pharmacother,1999,33(2):236-240.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部